clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Lung Neoplasms D008175 171 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Yamane N et al. [Multicenter evaluation of a newly developed microdilution test, brothMIC NTM to determine minimum inhibitory concentrations of antimicrobial agents for nontuberculous mycobacteria]. 2002 Rinsho Byori pmid:12014018
Ozawa S [Drug-drug interaction in pharmacogenetics and pharmacogenomics]. 2002 Rinsho Byori pmid:11925851
Tomita A et al. [Analysis of the macrolide resistance gene in penicillin-resistant Streptococcus pneumoniae]. 2006 Rinsho Byori pmid:16989397
Egashira T [Development and clinical application of invader assay--detection of resistant mutation to clarithromycin in Helicobacter pylori]. 2006 Rinsho Byori pmid:16548239
Kodama M and Fujioka T [Eradication therapy of Helicobacter pylori infection]. 2001 Rinsho Byori pmid:11307304
Fukuda Y et al. [The history of Helicobacter pylori]. 2001 Rinsho Byori pmid:11307300
Chen G et al. [The cause of failure of eradication treatment of Helicobacter pylori]. 2005 Rinsho Byori pmid:16190353
Ohe M and Kohno M [Three cases of idiopathic thrombocytopenic purpura showing an increase in the platelet count following clarithromycin treatment]. 2003 Rinsho Ketsueki pmid:14639954
Goto H et al. [Successful treatment of refractory idiopathic thrombocytopenic purpura by eradication of Helicobacter pylori]. 2001 Rinsho Ketsueki pmid:11828723
Sakabe H et al. [Successful treatment of long-standing iron-deficiency anemia in adults by eradication of Helicobacter pylori]. 2004 Rinsho Ketsueki pmid:15199751
MORITA R et al. Iron deficiency anemia successfully treated by Helicobacter pylori eradication in a patient with idiopathic thrombocytopenic purpura. 2009 Rinsho Ketsueki pmid:20009444
Yanagimachi M et al. [Cutaneous non-tuberculous mycobacterial infection following cord blood stem cell transplantation]. 2008 Rinsho Ketsueki pmid:18341040
Takahashi T et al. [Successful platelet recovery after the second eradication of Helicobacter pylori with metronidazole in two patients with chronic idiopathic thrombocytopenic purpura]. 2006 Rinsho Ketsueki pmid:16784096
Ohe M and Hashino S [Successful treatment with clarithromycin for Mixed phenotype acute leukemia, T/myeloid, NOS]. 2010 Rinsho Ketsueki pmid:20467229
Fujikawa K et al. [A case of Mycobacterium fortuitum meningitis following surgery for meningioma]. 2006 Rinsho Shinkeigaku pmid:17061701
AIDS patients have a new weapon against MAC infection. 1994 RN pmid:8128150
Sakatani M [Multi-drug resistant mycobacterial infection]. 1999 Ryoikibetsu Shokogun Shirizu pmid:10088372
Kimang'a AN et al. Helicobacter pylori: prevalence and antibiotic susceptibility among Kenyans. 2010 S. Afr. Med. J. pmid:20429490
Laving A et al. Effectiveness of sequential v. standard triple therapy for treatment of Helicobacter pylori infection in children in Nairobi, Kenya. 2013 S. Afr. Med. J. pmid:24300630
Bellelis P et al. Efficacy of a triple therapy for Helicobacter pylori eradication in a well-developed urban area in Brazil. 2004 Sao Paulo Med J pmid:15257365
Eisig JN et al. Therapeutic efficacy of ranitidine bismuth citrate with clarithromycin for seven days in the eradication of Helicobacter pylori in Brazilian peptic ulcer patients. 2003 Sao Paulo Med J pmid:12751338
Baba K et al. A case of sarcoidosis with multiple endobronchial mass lesions that disappeared with antibiotics. 2006 Sarcoidosis Vasc Diffuse Lung Dis pmid:16933475
Alsohaibani F et al. Prospective trial in Saudi Arabia comparing the 14-day standard triple therapy with the 10-day sequential therapy for treatment of Helicobacter pylori infection. Saudi J Gastroenterol pmid:26228365
Zullo A et al. Furazolidone-based therapies for Helicobacter pylori infection: a pooled-data analysis. Saudi J Gastroenterol pmid:22249086
Agah S et al. Comparison of azithromycin and metronidazole in a quadruple-therapy regimen for Helicobacter pylori eradication in dyspepsia. 2009 Oct-Dec Saudi J Gastroenterol pmid:19794266
Kekilli M et al. Inefficacy of triple therapy and comparison of two different bismuth-containing quadruple regimens as a firstline treatment option for helicobacter pylori. Saudi J Gastroenterol pmid:27748322
Rajendiran S et al. Increased protein carbonylation and decreased antioxidant status in anemic H. pylori infected patients: effect of treatment. 2012 Jul-Aug Saudi J Gastroenterol pmid:22824768
Hu JL et al. Optimized high-dose amoxicillin-proton-pump inhibitor dual therapies fail to achieve high cure rates in China. Saudi J Gastroenterol pmid:28937021
Abadi AT et al. High frequency of A2143G mutation in clarithromycin-resistant Helicobacter pylori isolates recovered from dyspeptic patients in Iran. 2011 Nov-Dec Saudi J Gastroenterol pmid:22064338
Dajani AI et al. Do probiotics improve eradication response to Helicobacter pylori on standard triple or sequential therapy? 2013 May-Jun Saudi J Gastroenterol pmid:23680708
Zhang SH et al. The effect of virulence genotypes of on eradication therapy in children. Saudi J Gastroenterol pmid:29652033
Al Majid FM Peritonitis due to Mycobacterium fortuitum following gastric banding. Saudi J Gastroenterol pmid:20339182
Shokrzadeh L et al. Antibiotic susceptibility profile of Helicobacter pylori isolated from the dyspepsia patients in Tehran, Iran. Saudi J Gastroenterol pmid:21727733
Hasan SR et al. Short-duration furazolidone therapy in combination with amoxicillin, bismuth subcitrate, and omeprazole for eradication of Helicobacter pylori. Saudi J Gastroenterol pmid:20065568
Khan MQ Helicobacter pylori Eradication Therapy in Nonulcer Dyspepsia is Beneficial. 2008 Saudi J Gastroenterol pmid:19568511
Wang J et al. Two-week triple therapy has a higher Helicobacter pylori eradication rate than 1-week therapy: A single-center randomized study. Saudi J Gastroenterol pmid:26655129
Pellicano R and Fagoonee S One or two weeks of treatment with Helicobacter Pylori ''standard'' triple therapy in the year 2015? Saudi J Gastroenterol pmid:26655127
Dajani A et al. Importance of Helicobacter pylori eradcation for maintenance of remission of drug associated peptic ulcer disease. Saudi J Gastroenterol pmid:19858579
Salem EM et al. Comparative study of Nigella Sativa and triple therapy in eradication of Helicobacter Pylori in patients with non-ulcer dyspepsia. 2010 Jul-Sep Saudi J Gastroenterol pmid:20616418
Bezmin Abadi AT et al. Inefficiency of rapid urease test for confirmation of Helicobacter pylori. Saudi J Gastroenterol pmid:21196663
Rajindrajith S et al. Helicobacter pylori infection in children. 2009 Saudi J Gastroenterol pmid:19568571
Ranganathan D et al. Mycobacterium fortuitum peritonitis in a patient receiving continuous ambulatory peritoneal dialysis. 2013 Saudi J Kidney Dis Transpl pmid:24029271
Vafaeimanesh J et al. Expression comparison of azithromycin and clarithromycin in triple-therapy regimens for eradication of Helicobacter pylori in hemodialysis patients. 2014 Saudi J Kidney Dis Transpl pmid:24434382
Alfaresi MS et al. Molecular prevalence of point mutations conferring resistance to clarithromycin in Helicobacter pylori in the United Arab Emirates. 2005 Saudi Med J pmid:15951866
Ghazzawi IM et al. Triple therapy with pantoprazole, clarithromycin and amoxicillin for eradication in patients with Helicobacter pylori positive duodenal ulcers. 2004 Saudi Med J pmid:15322588
Al-Mobeireek AF Rapidly growing mycobacterial pulmonary infection in association with severe gastroesophageal reflux disease. 2002 Saudi Med J pmid:12174240
Celen MK et al. Development of pneumatoceles after viral infection. 2006 Saudi Med J pmid:16830037
Bindayna KM Antibiotic susceptibilities of Helicobacter pylori. 2001 Saudi Med J pmid:11255612
Paakkanen R et al. Beneficial effect of clarithromycin in patients with acute coronary syndrome and complement C4 deficiencies. 2009 Scand. Cardiovasc. J. pmid:19365786
Bjerre M et al. Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: the CLARICOR trial. 2014 Scand. J. Clin. Lab. Invest. pmid:25026506